Company Interview / Cyclopharm ramps up its US rollout

Key Points:

Multi-site US hospital deals seen as key accelerator for Cyclopharm’s Technegas adoption Technegas positioned as a unique nuclear medicine lung imaging agent with global reach Strategy in the US focused on reimbursement, clinical validation and a growing sales force Growth outlook tied to wider respiratory applications and integration with AI-driven imaging

Cyclopharm (ASX:CYC) is targeting rapid expansion in the United States, with James McBrayer highlighting a new multi-site agreement with Northwestern Memorial HealthCare, following a recent deal with the University of Pennsylvania Health System. McBrayer views Northwestern as a key “lighthouse” site in Chicago and notes that both institutions sit among the top US hospitals, which he sees as validation of Cyclopharm’s US growth strategy and execution.

McBrayer describes Cyclopharm’s Technegas lung imaging technology as a nuclear medicine agent inhaled into the lungs, acting as an analogue for oxygen to show precisely where lung function and oxygen uptake occur. In his view, there is no direct competitor to Technegas, which is now present in 67 countries. He sees the US as the largest opportunity, with around half of the world’s nuclear medicine departments located there, and says multi-site agreements are accelerating adoption as initial installations lead to further rollouts.

The company’s US strategy, McBrayer states, has been deliberate: starting with clinical trial sites, securing reimbursement, then launching a dedicated sales force late last year. He points to a recently completed capital raise as providing sufficient funding and sees long-term growth in expanding beyond pulmonary embolism diagnosis into COPD, asthma and broader respiratory medicine, supported by emerging AI-driven imaging capabilities.